Glaxo
Executive Summary
FDA Associate Commissioner for Legislative Affairs Hugh Cannon is leaving the agency to join Glaxo, Inc. as director of federal agency relations. Cannon, 51, will remain in Washington and report to Glaxo VP-Federal Government Affairs Geoffrey Littlehale. Cannon's last day on the job is June 14; a successor has yet to be selected. The deputy associate commissioner for legislative affairs is Kay Holcombe. She has held that position for two months. Previously, she was exec VP at the Foundation for Biomedical Research since 1989.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth